PATENT COOPERATION TREATY

PCT

Translation INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 664677				FOR FURTHER ACTION		See Form PCT/IPEA/416					
International application No. PCT/JP2004/011333				International filing date (day/month/year) 06.08.2004		Priority date (day/month/year) 08.08.2003					
				onal classification and large of the second classificatio		47/38, A61P37/08					
Applicant SCHERING CORPORATION											
1.	1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.										
2.	This R	EPORT consists	of a total of	6	sheets, inclu	ding this cover sheet.					
3.	This re	eport is also acco	ompanied by Al	NNEXES, comprising:							
	a	(sent to the	applicant and	to the International Bu	reau) a total of	sheets, as follows:					
	sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).										
	sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.										
	b	7	International I	Bureau only) a total of (indicate type and nun	nber of electronic carrier(s))					
						, containing a sequence listing and/or tables					
			-	readable form only, as rative Instructions).	s indicated in the Sup	plemental Box Relating to Sequence Listing (see					
4.	This re	eport contains in	dications relati	ng to the following item	ıs:						
	\boxtimes	Box No. I	Basis of the	report							
		Box No. II	Priority								
		Box No. III	Non-establi	shment of opinion with	regard to novelty, inv	entive step and industrial applicability					
		Box No. IV	Lack of unit	ty of invention							
		Box No. V		atement under Article 3 d explanations supportin	• •	ovelty, inventive step or industrial applicability;					
		Box No. VI	Certain doc	uments cited							
		Box No. VII	Certain defe	ects in the international	application						
	\boxtimes	Box No. VIII	Certain obse	ervations on the interna	tional application						
Date of s	submiss	ion of the deman			Date of completion of	f this report					
Name and mailing address of the IPEA/JP				Authorized officer							
 Facsimil	le No.				Telephone No.						

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/JP2004/011333

Box No. 1	I Basis of the report	
	ith regard to the language, this report is based on the internation dicated under this item.	al application in the language in which it was filed, unless otherwise
	This report is based on translations from the original languag	
	which is the language of a translation furnished for the purport	oses of:
	international search (Rule 12.3 and 23.1(b))	
	publication of the international application (Rule 12.4)	
XX 7°4	international preliminary examination (Rule 55.2 and/o	
rece		report is based on (replacement sheets which have been furnished to the referred to in this report as "originally filed" and are not annexed to
	the international application as originally filed/furnished	
	the description:	
	pages	as originally filed/furnished
	pages*	received by this Authority on
	pages*	received by this Authority on
	the claims:	
		as originally filed/furnished
	nos.	
	nos.*	
	nos.*	received by this Authority on
	nos.*	received by this Authority on
	the drawings:	
	sheets	as originally filed/furnished
	sheets*	received by this Authority on
	sheets*	received by this Authority on
	a sequence listing and/or any related table(s) – see Suppleme	ental Box Relating to Sequence Listing.
	1	mur 2 on recump to sequence 215mg.
3.	The amendments have resulted in the cancellation of:	
	the description, pages	
	the claims, nos.	
	the drawings, sheets/figs	
	the sequence listing (specify):	
	any table(s) related to sequence listing (specify):	
4.	This report has been established as if (some of) the amendathey have been considered to go beyond the disclosure as file	ments annexed to this report and listed below had not been made, since ed, as indicated in the Supplemental Box (Rule 70.2(c)).
	the description, pages	
	the claims, nos.	
* If it	item 4 applies, some or all of those sheets may be marked "supe	

International application No.				
PCT/JP2004/011333				

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability citations and explanations supporting such statement				
1.	Statement			
	Novelty (N) Claims		1-18	_ YES
		Claims		_ NO
Inventive step (IS)		Claims	5	_ YES
		Claims	1-4, 6-18	_ NO
Industrial applicability (IA) Claims		Claims	1-18	_ YES
		Claims		_ NO

2. Citations and explanations (Rule 70.7)

Documents cited in the international search report:

Document 1: JP 57-035586 A, entire text

Document 2: JP 9-208495 A, claims 1 and 7; paragraphs [0010] and [0011]

Document 3: Dai Jusan Kai Nippon Yakkyokukata

Kaisetsusho, 1996, Kabushiki Kaisha Hirokawa

Shoten, A107, lines 24 to 30

Document 4: JP 6-157312 A, paragraphs [0002], [0006] and [0009]

Document 5: JP 11-029463 A, claims 1, 4 and 5, paragraph [0001]

Newly cited document:

Document 6: WO 2001/76607 A1 (Nichiiko Pharmaceutical Co., Ltd.), 18 October 2001, entire text

Claims 1 to 4 and 8 to 18

The invention set forth in claims 1 to 4 and 8 to 18 does not involve an inventive step in the light of documents 1 to 5.

Dry syrup is a dosage form which would be well known to a person skilled in the art, therefore it would be easy for a person skilled in the art to conceive of

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

attempting to obtain a dry syrup preparation for loratadine, which is a known drug, as set forth in document 1.

In addition, as indicated in documents 2 to 4, hydroxypropyl cellulose, other cellulose derivatives and saccharides such as sucrose are known as additives to dry syrup, therefore the use of these additives when obtaining a dry syrup for loratadine is a matter which a person skilled in the art could accomplish as necessary.

Moreover, document 5 indicates that by using hydroxypropyl cellulose it is possible to obtain an aqueous suspended solution with good redispersibility for a substance with poor solubility. It would therefore be easy for a person skilled in the art to predict the effect disclosed in this application, i.e. good dispersibility.

Claim 5

The invention set forth in claim 5 is novel and involves an inventive step.

According to the embodiment disclosed in the response to the written opinion submitted by the applicant, it is understood that when hydroxypropyl cellulose HPC-SSL which satisfies the requirements set forth in claim 5 is used, better dispersibility and antifoaming properties are obtained than for hydroxypropyl cellulose HPC-SL, whose viscosity falls outside the prescribed range. Moreover, none of the documents cited in the international search report or the newly cited document discloses or suggests this feature.

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/JP2004/011333

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Claims 6 and 7

The invention set forth in claims 6 and 7 does not involve an inventive step in the light of documents 1 to 4.

As set forth in documents 2 and 4, an alginate is known as an additive to dry syrup, therefore using these additives when obtaining a dry syrup containing lorated in a matter which a person skilled in the art could accomplish as necessary.

In addition, in reference to the description of this application, there is not even one embodiment which does not contain hydroxypropyl cellulose but contains only an alginate, therefore it is impossible to acknowledge that such an embodiment has a special effect in terms of dispersibility.

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claims 1 and 8-16

Claim 1 relates to a dry syrup comprising as an active ingredient a compound defined by the desired property of "binder that upon addition of water at use, provides a uniform dispersion". It appears from the description, paragraph [0012], that the "binder that upon addition of water at use, provides a uniform dispersion" refers to all of such binder compounds that any dry syrup having the same added thereto satisfies the requirements (i) to (v) recited in claim 12.

However, only examples wherein hydroxypropyl cellulose was added are disclosed in the description of this application. Thus, it appears that only some of the claimed compounds are disclosed within the meaning of PCT Article 5, so that the support by disclosure in the description within the meaning of PCT Article 6 is lacking.

Further, with respect to the "binder that upon addition of water at use, provides a uniform dispersion", as apparent from the above, whether or not compounds are the relevant binder compounds cannot be judged unless the final compositions are obtained. The scope of compounds with this property cannot be specified even if technical common knowledge at the time of filing of this application is taken into account. Therefore, claim 1 also fails to satisfy the requirement of clarity prescribed in PCT Article 6.

The same applies to claims 8-16.